Trinity sets up flagship office in Europe led by former Syneos manager

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/LewisTsePuiLung)
(Image: Getty/LewisTsePuiLung)

Related tags: Consulting

The strategic advisory company, Trinity, opens a new office in Germany, with leadership joining from Syneos Health to work “hand-in-hand” with biopharma clients.

Trinity – working with more than 100 biopharmaceutical and medical device clients annually – provides a range of services, including benchmarking solutions. The company’s subsidiary, TGaS Advisors, has five offices throughout the US.

Leading Trinity’s Europe operations is Alexander Fink, managing partner Europe, who joins the company from Syneos Health, where he built the European commercial strategy consulting business, and recently headed the global product and franchise strategy service line as senior managing director.

A principal on the leadership team, Jackson Carroll also joins from Syneos, where he was a senior engagement manager in the company’s commercial advisory group. He has more than 17 years of management consulting experience.

“Europe represents the second largest regional biopharmaceutical market in the world and commercial biopharmaceutical leaders recognize the importance of having a specific European strategy to successfully launch and manage their products in this complex set of markets,”​ said Fink, speaking to the company’s decision to open its flagship office in Munich, Germany.

“As an advisory company who works hand-in-hand with biopharmaceutical companies, we saw the value in opening an office in Europe with team members who bring European specialist experience,”​ he told us. 

Fink said the office location is ideal as it is located centrally between the life sciences hubs in Europe and is accessible globally.

“There will always be demand for high-quality professional services from experienced professionals and Europe is the fastest growing professional services market with the highest demand,”​ he added.

“With increasing pressure to maximize returns, commercial leaders in biopharmaceutical companies insist on having the support of advisors who do not just have life sciences commercial experience but also bring specialist experience relevant to their therapy area and target regions and the tools to optimally support them.”

Related topics: Globalization, Markets & Regulations

Related news

Show more

Follow us


View more